

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE

Milan, 19 December 2018 – Please be informed that the **Directors' Report** relating to sole item of the agenda of the Ordinary Shareholders' Meeting (Appointment of a new Board of Directors) called for February 5th 2019, single call, is available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "linfo" storage mechanism (www.linfo.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393

e-mail: investorelations@recordati.it

Media Relations
Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com